Accelerate Diagnostics enters stalking horse asset purchase agreement with Indaba for $41.95M credit bid

Accelerate Diagnostics, Inc

Agreement to sell substantially all assets to Indaba Starling for $41,952,668 credit bid plus assumed liabilities.
Sale subject to Bankruptcy Court approval and competing bids under Section 363 of Bankruptcy Code.
Common stockholders expected to experience significant or complete loss on investment.
Buyer is affiliate of Indaba Capital, existing secured noteholder.
Closing conditions include Court order by July 28, 2025, and other conditions.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.